hormone-resistant asthma
Conditions
Interventions
steroid resistant asthma group:None
Non-steroid resistant asthma group:None
normal control group:None
Sponsors
The First Hospital of Shanxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Inclusion criteria for SRA patients and non-SRA patients: (1) Lived in Yingze District, Xinghualing District or Xiaodian District, Taiyuan City for more than 5 years; (2) Based on past outpatient, emergency and hospitalization records of the Department of Respiratory Medicine, the First Affiliated Hospital of Shanxi Medical University; (3) Asthma patients who are diagnosed with asthma strictly according to the asthma diagnostic criteria and have no other respiratory diseases or allergic diseases; (4) Asthma patients whose forced expiratory volume in 1 second improves by <15% (insensitive to hormones) after 2 weeks of treatment with appropriate doses of glucocorticoids (5) Aged between 18-64 years old; (6) Not smoking or quitting smoking for more than 1 year; (7) Exclude other major diseases; (8) Voluntarily sign the informed consent form. 2. Inclusion criteria for normal control population: (1) Choose to live in a community in Yingze District for more than 5 years; (2)Age 18-64 years old; (3) Not smoking or quitting smoking for more than 1 year; (4) Those who do not have respiratory diseases or other serious diseases and voluntarily sign an informed consent form can be included in the research team;
Exclusion criteria
Exclusion criteria: (1) Those who do not meet any of the inclusion criteria; (2) Patients with concurrent infections or high fever within 4 weeks before screening, including but not limited to acute bronchitis, pneumonia, sinusitis, urinary tract infection or cellulitis; (3) Combined with tuberculosis or lung cancer; (4) Those with significant pulmonary hypertension or severe right heart failure who are judged by the researcher to be unfit to participate in the trial; (5) People with severe cardiovascular disease who have one of the following conditions: a. Severe hypertension occurs within 6 weeks and is not controlled after treatment (=160/100 mmHg); b. Myocardial infarction occurs within 6 months; c. Unstable angina pectoris within 6 months; (6) Coagulation parameters: international normalized ratio (INR) > 2, prothrombin time (PT) prolonged > 1.5 times ULN; (7) Other diseases or comorbidities that may interfere with the testing procedure (such as being unable to tolerate interruption of auxiliary oxygen supply during pulmonary function tests) or, based on the researcher's judgment, may affect trial participation or may put patients at risk ; (8) History of thrombotic events (including stroke and transient ischemic attack) within 12 months; (9) The researcher determines that the life expectancy is <4 years due to other diseases; (10) Major surgery is planned during treatment; (11) Women who are pregnant, breastfeeding or planning to become pregnant during the trial; patients with mental illness; (12) Those who are judged by the researcher to be unfit to participate in the trial;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulmonary fuction test; | — |
Secondary
| Measure | Time frame |
|---|---|
| Questionaire survey data; | — |
Countries
China
Contacts
Public ContactKong Xiaomei
The First Hospital of Shanxi Medical University
Outcome results
None listed